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Abstract 
Evodiamine has therapeutic potential against cancers. This study was designed to investigate 
whether combination therapy with gemcitabine and evodiamine enhanced antitumor efficacy 
in pancreatic cancer. In vitro application of the combination therapy triggered significantly 
higher frequency of pancreatic cancer cells apoptosis, inhibited the activities of PI3K, Akt, 
PKA,  mTOR  and  PTEN,  and  decreased  the  activation  of  NF-κB  and  expression  of 
NF-κB-regulated products. In vivo application of the combination therapy induced significant 
enhancement of tumor cell apoptosis, reductions in tumor volume, and inhibited activation of 
mTOR and PTEN. In conclusion, evodiamine can augment the therapeutic effect of gem-
citabine in pancreatic cancer through direct or indirect negative regulation of the PI3K/Akt 
pathway. 
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Introduction 
Pancreatic cancer has a high incidence of local 
recurrence and develops distant metastasis, leading to 
extremely  poor  prognosis  (1).  Many  patients  with 
locally advanced or metastatic pancreatic cancer are 
stable on chemotherapy with gemcitabine. Although 
gemcitabine  is  the  most  potent  and  standard  treat-
ment of pancreatic cancer (2, 3), the tumor response 
rate  of  gemcitabine  is  below  10%.  Previous  studies 
have shown that treatment with gemcitabine results 
in  the  median  survival  time  of  about  five  to  six 
months (4, 5). Furthermore, although treatment with 
gemcitabine  and  erlotinib  or  capecitabine  benefits 
patients  with  pancreatic  cancer,  these  therapeutic 
strategies  fail  to  significantly  prolong  the  survival 
time  of  pancreatic  cancer  patients  (6,  7).  Therefore, 
development of new chemotherapeutic approaches to 
enhance the therapeutic effect and reduce the devel-
opment of drug-resistance will be of great significance 
in the clinical management of pancreatic cancer.  
Constitutive  activation  of  nuclear  factor-κB 
(NF-κB)  can  promote  cell  proliferation,  inhibit  cell 
apoptosis and regulate the expression of genes asso-
ciated with the tumor-related invasion (8) and angio-
genesis (9, 10), reflecting the aggressive behavior of 
pancreatic  cancer  (11).  Notably,  gemcitabine  can 
up-regulate  NF-κB  expression  in  pancreatic  cancer 
cells,  which  is  associated  with  the  development  of 
chemoresistance and poor outcome in cancer patients, 
including  patients  with  pancreatic  cancer  (12-16). 
PI3K and Akt are kinases that play a critical role in 
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human cancer. Asano et al. (17) has reported that PI3K 
and Akt are activated due to aberrant PTEN expres-
sion  and  essential  for  the  function  of  constitutively 
activated NF-κB in pancreatic cancer. Another report 
has shown that PI3K/Akt pathway is constitutively 
activated in a majority of human pancreatic cancer cell 
lines and PI3K/Akt has emerged as a promising tar-
get  for  therapeutic  intervention  (18).  Arlt  et al.  (16) 
suggested that PI3K/Akt was not involved in gem-
citabine  resistance,  but  another  report  (19)  demon-
strated that Akt activity is necessary for the induction 
of  NF-κB  after  gemcitabine  treatment,  though  the 
mechanism does not involve activation of Akt.  
Evodiamine  is  one  of  the  main  constituents  of 
Evodiae  fructus  (20)  and  has  been  shown  to  exhibit 
anti-tumor properties (21). The apoptotic activity of 
evodiamine was shown to be due to its inhibition of 
NF-κB activation via suppression of IκB kinase ac-
tivity,  which  leads  to  inhibition  of  NF-κB-regulated 
gene  products  such  as  XIAP,  Bcl-2,  and  Bcl-xL  (8). 
Previous  study  has  also  revealed  the  molecular 
mechanism  by  which  evodiamine  increases  the  ex-
pression  of  proapoptotic  Bax  and  decreases  that  of 
anti-apoptotic Bcl-2, which amplified the activation of 
the caspase cascade, triggering consequent responses 
and cell death (21-23). PI3K was also found to exhibit 
essential regulatory effects on functions of SIRT1, p53 
and  other  signaling  proteins  involved  in  evodia-
mine-induced  A375-S2 cell  death  (24,  25). Based  on 
these reports, we hypothesized that evodiamine may 
augment  the  gemcitabine-induced  anti-tumor  effect 
on  pancreatic  cancer  via  direct  or  possibly  indirect 
inhibition of the PI3K/Akt pathway targeting NF-κB. 
 This  study  showed  that  evodiamine  inhibited 
the  spontaneous  and  gemcitabine-induced  NF-κB 
activation,  and  the  expression  of  NF-κB-regulated 
proteins  in  SW1990  cells.  Importantly,  evodiamine 
inhibited the activation of PI3K/Akt pathway, phos-
phorylation  of  PTEN  and  mammalian  target  of  ra-
pamycin  (mTOR),  and  activity  of  cAMP-dependent 
protein  kinase A  (PKA) that was not influenced by 
gemcitabine. Our data suggest that evodiamine may 
augment  the  therapeutic  effect  of  gemcitabine  in 
pancreatic cancer through direct or indirect negative 
regulation  of  the  PI3K/Akt  pathway  that  targets 
NF-κB. 
Materials and Methods 
Reagents 
Evodiamine (purity: >99%) was purchased from 
Sigma (St. Louis, MO, USA), and dissolved in dime-
thylsulfoxide  (DMSO)  at  0.2  mmol/L  to  make  the 
stock solution. Gemcitabine was purchased from Ely 
Lilly (Bad Homburg, Germany) and dissolved in ster-
ile  saline  at  50  g/L  for  stock  solution,  with  a  ﬁnal 
concentration of DMSO at <0.1%. Rabbit polyclonal 
antibodies  against  phospho-PTEN(Ser380/Thr382/ 
383) and PI3K(Tyr458) were purchased from Cell Sig-
naling Technology (Beverly, MA, USA). Rabbit poly-
clonal  antibodies  against  Bax  and  Bcl-2,  phos-
pho-mTOR(Ser2448),  Rictor-mTOR,  phos-
pho-Akt(Ser473), rabbit monoclonal antibody against 
NF-κB(p65), survivin and active caspase 3 were pur-
chased from Abcam (Cambridge, UK). The in Situ Cell 
Death Detection Kit was purchased from Roche (Ba-
sel, Switzerland). 
Cell culture 
Human pancreatic tumor cell line, SW1990, was 
purchased from the American Type Culture Collec-
tion (ATCC, Manassas, VA, USA) and cultured in 
RPMI-1640  supplemented  with  10%  heat-incubated 
fetal  bovine  serum  (FBS;  Invitrogen,  Carlsbad,  CA, 
USA), 100 units/mL of penicillin, and 100 g/mL of 
streptomycin and incubated at 37˚C in a humidified 
5% CO2 atmosphere. Some SW1990 cells were stably 
transfected  with  luciferase,  as  previously  described 
for  Panc-1  cells  (26).  Luciferase-transfected  SW1990 
cells were routinely cultured in the same condition as 
SW1990 cells. 
MTT assay  
The  cytotoxicity  of  individual  drugs  against 
SW1990  cells  was  determined  by  the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide assay (MTT; Sigma), as previously described 
(27).  Briefly,  SW1990  cells  at  5×103  cells/well  were 
cultured  in  96-well  microtiter  plates  overnight  and 
treated in triplicate with 20 mol/L of gemcitabine for 
24 h, and/or 1.0 μmol/L of evodiamine for 48 h. Un-
treated cells in medium alone were used as controls. 
The viability of control cells was designated as 100% 
and  the  viability  of  other  experimental  groups  was 
calculated relative to controls. 
In vitro treatment protocol and apoptosis assay  
SW1990 cells at 2×105/mL were cultured over-
night in six-well plates and treated in triplicate with 
20  mol/L  of  gemcitabine  for  24  h,  and/or  1.0 
μmol/L  of  evodiamine  for  48  h.  Untreated  cells  in 
medium alone were used as controls. Subsequently, 
the cells were harvested, washed and stained with 10 
µL of Annexin V and 5 µL of propidium iodide (PI) in 
the dark for 15 min at room temperature, according to 
the manufacturer’s instructions (Biosea, Beijing, Chi-
na). The apoptotic cells were detected and measured 
by  flow  cytometer  (Epics  AltraII;  Beckman  Coulter, Int. J. Biol. Sci. 2012, 8 
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Fullerton, CA, USA) and examined under an inverse 
ﬂuorescent microscope.  
Electrophoretic mobility shift assay (EMSA) 
NF-κB activity was evaluated by EMSA analysis, 
as  described  elsewhere  (28).  Nuclear  proteins  were 
extracted from treated or untreated cells and protein 
concentrations were determined by BCA assay. The 
Biotin end-labeled DNA duplex of sequence 5′-AGT 
TGA GGG GAC TTT CCC AGG C-3′ and 3′-TCA ACT 
CCC CTG AAA GGG TCC G-5′ containing a putative 
binding site for NF-κB was incubated with the nuclear 
extracts.  Subsequently,  the  DNA-protein  complexes 
were  subjected  to  a  6%  native  polyacrylamide  gel 
electrophoresis  (PAGE)  and  transferred  to  a  nylon 
membrane  (Pierce,  Rockford,  IL,  USA),  and 
cross-linked for 15 min on a UV transilluminator, fol-
lowed by detection using the LightShiftTM Chemilu-
minescent EMSA kit (Pierce), according to the manu-
facturers’ instructions. The membranes were exposed 
to X-ray films and the relative intensities were ana-
lyzed using the NIH Image 1.62 package. The nuclear 
extracts  from  unstimulated  gastric  cancer  SGC7901 
cells were used as negative control and SGC7901cells 
stimulated with 50 ng/mL TNFα were used as posi-
tive controls. 
Western blot analysis 
SW1990  cells  (2×106/plate)  were  treated  with 
drug(s) as described above and harvested. Total pro-
teins were extracted and concentrations were deter-
mined  by  the  BCA  assay.  The  lysates  (20  g/lane) 
were  separated  by  8-12%  sodium  dodecyl  sul-
fate–PAGE and transferred onto polyvinylidene fluo-
ride (PVDF) membranes. After being blocked with 5% 
fat-free milk, the membranes were probed with indi-
vidual primary antibodies overnight at 4C and the 
bound  antibodies  were  detected  with  horseradish 
peroxidase  (HRP)-conjugated  goat  anti-rabbit  IgG. 
The formed immunocomplex was visualized by en-
hanced chemiluminescence reagent (ECL, Pierce) and 
exposed  to  X-ray  films.  Quantitative  data  were  ex-
pressed  as  mean%SD  of  the  relative  levels  of  the 
objective protein and control -actin of each group of 
cells from three independent experiments. 
Measurement of intracellular cAMP concen-
tration  
 SW1990  cells  (2×106/plate)  were  treated  with 
drug(s) as described above and harvested. cAMP lev-
els were determined by cAMP enzyme immunoassay 
kit  following  the  manufacturer's  instructions  (Cay-
man Chemical Co., Ann Arbor, MI, USA). The protein 
concentration of total cell lysate was used as loading 
control, and the results were expressed as picomoles 
of cAMP per microgram of total protein.  
Measurement of intracellular PKA activity  
 SW1990 cells were treated drug(s) as described 
above and collected with PKA extraction buffer before 
breakdown under 4˚C. Individual supernatants were 
collected by centrifugation (11,000×g, 10 min at 4˚C) to 
detect  PKA  activity  using  a  PKA  activity  assay  kit 
(Upstate, Lake Placid, NY, USA).  
Experimental animals and protocols 
Female BALB/c nude mice at four to six weeks 
of age were purchased from the Shanghai Laboratory 
Animals Center (China). All animals were housed in a 
specific pathogen-free facility. The experimental pro-
tocols involving animals were approved by the Ani-
mal  Research  and  Ethical  Committee  of  Wenzhou 
Medical College.  
To establish the SW1990 pancreatic cancer cells 
xenograft  tumor  model,  individual  mice  were  im-
planted  subcutaneously  with  2×106  SW1990  cells  in 
200 μL of PBS on the back of each animal and moni-
tored for the development of tumors for up to three 
weeks  post-implantation.  When  tumors  reached  ~5 
mm  in  one  dimension  (length,  width,  or  height 
measured  by  Vernier  calipers),  the  mice  were  ran-
domized  and  treated  intraperitoneally  (IP)  with  sa-
line, gemcitabine alone (125 mg/kg) (29), evodiamine 
alone (10 mg/kg) (30), or combined gemcitabine (80 
mg/kg)  with  evodiamine  (10  mg/kg)  every  three 
days for up to 30 days post-implantation (n=12 per 
group). The experimental protocols are illustrated in 
Figure 1. One week after the last treatment, animals 
were  weighed,  sacrificed  and  the  tumors  were  ex-
cised. The final tumor volume was estimated by the 
following formula: V=2/3πr3, where r is the mean of 
the three dimensions (length, width, and height). A 
portion  of  the  tumor  tissue  was  formalin-fixed  and 
paraffin-embedded  for  subsequent  apoptosis  assay 
and immunohistochemistry analysis. 
Luciferase-transfected  SW1990  cells  xenograft 
tumor  models  were  established  by  subcutaneously 
inoculating  the  cells  into  the  bilateral  abdominal 
flanks (three places on each side) of nude mice. After 
three weeks of implantation, a total of 48 nude mice 
were randomized into four treatment groups (n=12) 
based on the bioluminescence measured after the first 
IVIS imaging. The treatment protocol of each group 
was the same as described above. One week after the 
last treatment, the numbers of tumors that had grown 
in  each  mouse  were  monitored  by  the  biolumines-
cence IVIS Imaging System 200 (Caliper Life Sciences, 
Hopkinton, MA, USA) using a cryogenically cooled Int. J. Biol. Sci. 2012, 8 
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imaging  system  coupled  to  a  data  acquisition  com-
puter running Living Image software (Xenogen Corp., 
Alameda,  CA,  USA).  Before  imaging,  animals  were 
anesthetized  by  asphyxiation  in  an  acrylic  chamber 
filled with 2.5% isoflurane/air mixture. Immediately 
afterwards, mice were intraperitoneally (i.p.) injected 
with 40 mg/mL D-luciferin potassium salt in PBS at a 
dose of 150 mg/kg. After 10 min of incubation with 
luciferin, mice were placed in a prone position and a 
digital grayscale animal image was acquired followed 
by  acquisition  and  overlay  of  a  pseudocolor  image 
representing the spatial distribution of detected pho-
tons emerging from active luciferase within the ani-
mal. Signal intensity was quantified as the sum of all 
detected  photons  within  the  region  of  interest  per 
second.  
In situ detection of apoptotic cells in tumor 
tissue 
The apoptotic tumor cells in the tumor tissues 
were characterized by the terminal deoxynucleotidyl 
transferase-mediated  deoxyuridine  tri-phosphate 
nick-end labeling (TUNEL) method using the In Situ 
Cell Death Detection Kit, according to the manufac-
turers’  instruction.  The  tumor  tissue  sections  were 
subjected to TUNEL analysis and apoptotic cells were 
examined under a laser scanning confocal microscope 
with 400x observation camera. Images were captured 
and  a  total  of  10  fields  with  strongest  fluorescence 
from individual tissue samples were examined. The 
integrated optical density (IOD) was analyzed by us-
ing Image Pro Plus software (MediaCybernetics, Be-
thesda,  MD,  USA).  Statistical  differences  between 
different groups were then analyzed. 
Immunohistochemistry detection of phos-
pho-mTOR(Ser2448) and phos-
pho-PTEN(Ser380) by  
Sections of paraffin-embedded pancreatic cancer 
tissues were deparaffinized and rehydrated prior to 
non-specific  antigen  blocking  with  goat  serum.  Im-
munostaining  was  performed  using  primary  anti-
bodies  specific  for  phospho-mTOR(Ser2448)  or 
phospho-PTEN(Ser380), followed by staining with the 
appropriate  HRP-conjugated  secondary  antibodies. 
The immunostained sections were developed in dia-
minobenzidine  (DAB)  and  counterstained  with  a 
weak solution of haematoxylin solution. The stained 
slides  were  dehydrated  and  mounted  in  Permount 
(Fisher Scientific, Pittsburg, PA, USA) and visualized 
on a light microscope (Olympus, Tokyo, Japan). Im-
ages were captured with an attached camera linked to 
a  computer.  For  data  quantification,  IOD  level  was 
analyzed by using the Image Pro Plus 6.0 software. 
Twelve  nude  mice  were  included  for  each  experi-
mental  group.  One section was  obtained from each 
animal.  At  least  six  fields  were  randomly  selected 
from each section. The average IOD levels in different 
groups were then compared by statistical analysis. 
Statistical analysis 
Data  shown  are  representative  images  or  ex-
pressed as mean%±SD of each group. The difference 
among  groups  of  cells  or  mice  was  analyzed  by 
Chi-square (X2) test or ANOVA, followed by post hoc 
Student’s  t-test using the  SPSS v17.0 software (Chi-
cago, IL, USA). A P-value of less than 0.05 was con-
sidered statistically significant. 
 
 
Figure 1. Schematic illustration of the experimental protocol. 
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Results 
Cytotoxicity of evodiamine plus gemcitabine 
against SW1990 cells in vitro 
As  shown  by  MTT  assays  (Fig.  2A),  treatment 
with  evodiamine  or  gemcitabine  alone  reduced  the 
cell  viability  by  nearly  42%  and  57%,  respectively. 
Treatment  with  combination  of  evodiamine  and 
gemcitabine significantly reduced the cell viability by 
80%.  Further  analysis  by  cell  apoptosis  assay  indi-
cated that single evodiamine increased the apoptotic 
rate from 12.6% to 28.6% and single gemcitabine in-
creased the apoptotic rate from 12.6% to 34.2%, while 
treatment with evodiamine plus gemcitabine induced 
nearly 57.6% of cell apoptosis (Fig. 2B and C). These 
data are consistent with results from cell growth in-
hibition studies using MTT, suggesting that the loss of 
viable  cells  by  evodiamine  and/or  gemcitabine  is 
partly due to the induction of cell apoptosis.  
Effect of evodiamine on the gemcita-
bine-induced NF-B activity in vitro  
SW1990 cells were treated with 20 M of gem-
citabine  for  varying  periods  and  the  DNA  binding 
activity of NF-κB in the nuclear extracts was charac-
terized by EMSA. As shown in Fig. 3A, SW1990 cells 
in the absence of gemcitabine displayed low levels of 
DNA binding activity, indicating low levels of spon-
taneous NF-κB activation. Treatment of SW1990 cells 
with gemcitabine for 24 h increased the DNA binding 
activity  of  NF-κB  by  436%  in vitro,  then  activity  of 
NF-κB gradually decreased to nearly a normal level at 
72 h after treatment (Fig. 3A). Treatment with differ-
ent doses of evodiamine inhibited the DNA binding 
activity of NF-κB in SW1990 cells (Fig. 3B). More im-
portantly,  treatment  with  gemcitabine  plus  evodia-
mine  significantly  reduced  the  DNA  binding  of 
NF-κB, as compared with that of gemcitabine treat-
ment or control cells (Fig. 3C). Therefore, treatment 
with  evodiamine  effectively  inhibited  the  gemcita-
bine-induced  NF-κB  activation  in  vitro,  which  may 
contribute to inducing more SW1990 cells apoptosis.  
 
Figure 2. Treatment with evodiamine plus gemcitabine inhibits the proliferation and induces apoptosis of SW1990 cells in 
vitro. SW1990 cells at 2×10
5/mL were cultured overnight in six-well plates and treated in triplicate with 20 mol/L of 
gemcitabine for 24 h, and/or 1.0 μmol/L of evodiamine for 48 h. Untreated cells in medium alone were used as controls. (A) 
Proliferation of SW1990 cells. (B) Representative dot-plots illustrating apoptotic status in SW1990 cells. (C) The percentage 
of SW1990 cell apoptosis. Data are expressed as mean%SD of each group of cells from three separate experiments. Evo: 
Evodiamine; Gem: Gemcitabine. *P<0.05 vs. control. **P<0.05 vs. cells treated with single drug or control.  Int. J. Biol. Sci. 2012, 8 
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Figure 3. Effect of evodiamine on the spontaneous and gemcitabine-induced NF-κB activation in vitro. (A) Gemcitabine (20 
mol/L) induces NF-B activation in SW1990 cells, as evidenced by EMSA supershift experiment. (B) Treatment with 
evodiamine for 48 h inhibits NF-B activation in SW1990 cells. (C) SW1990 cells at 2×10
5/mL were cultured overnight in 
six-well plates and treated in triplicate with 20 mol/L of gemcitabine for 24 h, and/or 1.0 μmol/L of evodiamine for 48 h. 
Untreated cells in medium alone were used as controls. Treatment with evodiamine attenuates the gemcitabine-induced 
NF-B activation in SW1990 cells. Equal protein loading was ensured by immunoblotting 10 μg of nuclear protein with 
anti-retinoblastoma antibody. Data are representative images (left column) and expressed as mean%SD of the relative 
levels of NF-B activation in SW1990 cells from tree separate experiments (right column). The nuclear extracts from 
unstimulated gastric cancer SGC7901 cells were used as negative control and SGC7901 cells stimulated with 50 ng/mL 
TNFα were used as positive controls. +: positive control; –: negative control; Evo: Evodiamine; Gem: Gemcitabine. *P<0.05 
vs. control. 
#P<0.05 vs. untreated cells or cells treated with gemcitabine. **P<0.05 vs. untreated cells; *
# P>0.05 vs. untreated 
cells; 
##P<0.05 vs. untreated cells.  Int. J. Biol. Sci. 2012, 8 
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Evodiamine inhibits gemcitabine-induced ex-
pression of NF-κB and modulates the expres-
sion of apoptosis-related proteins in SW1990 
cells  
Western  blot  analysis  showed  that  treatment 
with  evodiamine  significantly  down-regulated  the 
expression of NF-κB/p65 in SW1990 cells and its in-
hibitory effects were dose-dependent (Fig. 4A and B). 
Furthermore, while treatment with gemcitabine sig-
nificantly up-regulated the expression of NF-κB/p65, 
as  compared  with  that  in  control,  treatment  with 
evodiamine  significantly  mitigated  the  spontaneous 
and  gemcitabine-induced  expression  of  NF-κB/p65 
(Fig. 4C and D). Evodiamine signiﬁcantly decreased 
the  expression  of  Bcl-2  and  survivin,  while  active 
caspase-3 and Bax were up-regulated (Fig. 4C and D). 
Reduced ratio of Bcl-2/Bax was seen in combination 
treatment group (Fig. 4E).  
 
 
Figure 4. Treatment with evodiamine modulates the expression of NF-κB and the NF-κB-targeted proteins in vitro. (A) 
Treatment with evodiamine for 48 h inhibits the expression of NF-κB/p65 in a dose-dependent manner. (B) Quantification 
of NF-κB/p65 was performed by assigning a value of 1 to the group without evodiamine treatment. (C) SW1990 cells at 
2×10
5/mL were cultured overnight in six-well plates and treated in triplicate with 20 mol/L of gemcitabine for 24 h, and/or 
1.0 μmol/L of evodiamine for 48 h. Untreated cells in medium alone were used as controls. The relative levels of NF-κB/p65, 
Bcl-2 and Bax expression and active caspase-3 in SW1990 cells. (D) Quantification was performed by assigning a value of 1 
to the control group. (E) Bcl-2/Bax ratio was quantified by assigning a value of 1 to the control group. Evo: Evodiamine; Gem: 
Gemcitabine. *P<0.05 vs. controls; **P<0.05 vs. control or gemcitabine alone group. 
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Figure 5. Western blot analysis illustrating the effect of evodiamine on phospho-mTOR(Ser2448), Rictor-mTOR, phos-
pho-PTEN(Ser380/Thr382/383), and their downstream substrates PI3K(Tyr
458), phospho-Akt(Ser473) protein expression in 
SW1990 cells. SW1990 cells at 2×10
5/mL were cultured overnight in six-well plates and treated in triplicate with 20 mol/L 
of gemcitabine for 24 h, and/or 1.0 μmol/L of evodiamine for 48 h. Untreated cells in medium alone were used as controls. 
(A) Treatment with evodiamine or evodiamine plus gemcitabine inhibits the expression of phospho-mTOR(Ser2448), 
Rictor-mTOR, phospho-PTEN(Ser380/Thr382/383), PI3K(Tyr
458), and phospho-Akt(Ser473) protein. (B) The relative levels 
of phospho-mTOR(Ser2448), Rictor-mTOR, phospho-PTEN(Ser380/Thr382/383), PI3K(Tyr
458), and phospho-Akt(Ser473) 
in SW1990 cells. Quantification was performed by assigning a value of 1 to the control group. (C) Effect of evodiamine or 
evodiamine plus gemcitabine on cAMP concentration in SW1990 cells. (D) Effect of evodiamine or evodiamine plus gem-
citabine on PKA activity in SW1990 cells. Evo: Evodiamine; Gem: Gemcitabine. 
#P>0.05 vs. control; *P<0.05 vs. control; 
**P<0.05 vs. control or cells treated with gemcitabine alone.  
 
Evodiamine inhibits the phosphorylation of 
PI3K, Akt, PTEN and mTOR in SW1990 cells  
Evodiamine  significantly  down-regulated  the 
expression  of  phospho-Akt(Ser473),  which  was  not 
influenced by gemcitabine, and treatment with evo-
diamine plus gemcitabine also significantly inhibited 
the  phosphorylation  of  Akt.  Evodiamine  or  evodia-
mine plus gemcitabine markedly reduced the expres-
sion  of  PI3K(Tyr458),  phospho-PTEN  and  phos-
pho-mTOR, which were not significantly influenced 
by gemcitabine. Evodiamine or evodiamine combined 
with  gemcitabine  down-regulated  the  expression  of 
Rictor-mTOR, which was not modulated by gemcita-
bine. 
Evodiamine inhibits cAMP concentration and 
PKA activity 
 Evodiamine  or  evodiamine  plus  gemcitabine 
decreased cAMP concentration in SW1990 cells (Fig. 
5C). PKA is the primary mediator of cAMP activity 
and a key regulatory enzyme responsible for  many 
normal  cellular  processes,  such  as  cell  growth  and 
metabolism.  We  found  that  evodiamine  or  evodia-Int. J. Biol. Sci. 2012, 8 
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mine plus gemcitabine caused significant reduction in 
PKA  activity  (Fig.  5D),  which  was  similar  to  the 
drug-induced  effects  observed  for  phos-
pho-Akt(Ser473) and PI3K(Tyr458). 
Antitumor effect of evodiamine plus gemcita-
bine on the growth of implanted pancreatic 
tumors in vivo 
We  examined  the  effects  of  evodiamine  and 
gemcitabine, alone or in combination, on the growth 
of subcutaneously implanted pancreatic tumors (Fig. 
6A). Analysis of the final tumor volumes measured on 
day  37  after  the  start  of  treatment  revealed  that 
treatment with gemcitabine or evodiamine alone led 
to  significantly  slower  growth  than  treatment  with 
saline alone (Fig. 6B) (P<0.05 vs. controls). The final 
tumor volumes on day 37 of treatment  in the mice 
treated  with  combination  of  evodiamine  plus  gem-
citabine were further significantly minimized (Fig. 6B) 
(P0.05  vs.  control  or  gemcitabine-treated  mice).  A 
similar pattern of inhibitory effect was observed in the 
dissected tumor weights (Fig. 6C).  
 
Figure 6. Evodiamine potentiates the effect of gemcitabine in blocking the growth of pancreatic cancer in nude mice. After 
three weeks of implantation, a total of 48 nude mice were randomized into four treatment groups (n=12 per group) based 
on the bioluminescence measured after the first IVIS imaging. (A) Photographs of subcutaneously implanted pancreatic 
tumors on day 37 of treatment. Combination of evodiamine with gemcitabine significantly inhibited tumor growth. (B) 
Tumor volumes in mice measured on the last day of the experiment (Day 37) (n=12). (C) The tumor weights from individual 
groups of mice. (D) Bioluminescence IVIS images of subcutaneously implanted pancreatic tumors in live, anesthetized mice. 
(E) The amount of tumor in each nude mouse, as measured by live IVIS imaging on day 37 of treatment (n=12). Evo: Evo-
diamine; Gem: Gemcitabine. Points are and columns represent mean values; bars represent SD. *P<0.05 vs. control; 
**P<0.05 vs. control or mice treated with single agent. Int. J. Biol. Sci. 2012, 8 
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The enhanced antitumor effect caused by com-
bination of evodiamine plus gemcitabine was further 
demonstrated  in  the  luciferase-transfected  SW1990 
pancreatic  cancer  cells  xenograft  tumor  model. 
Measurements  of  bioluminescence  by  IVIS  imaging 
(Fig. 6D and E) indicated that the amount of tumors in 
the combined evodiamine plus gemcitabine treatment 
group was lower than in any other group. 
Before  treatment,  the  average  body  weight  of 
mice was not significantly different among the four 
experimental  groups.  However,  measurement  of 
mouse body weights on day 37 of treatments revealed 
that the body weight in the control group, evodiamine 
therapy group, gemcitabine therapy group and com-
bination therapy group was 16.3±1.53 g, 17.2±1.67 g, 
13.2±1.54 g, and 15.7±1.54 g, respectively. The mean 
body  weight  in  the  mice  treated  with  gemcitabine 
alone was significantly less than other groups of mice. 
The  potent  inhibition  on  the  growth  of  implanted 
tumors and the maintained body weight in the evo-
diamine-treated mice suggested that evodiamine im-
proved  the  tumor-  and  gemcitabine-related  deterio-
ration in mice. 
Treatment with evodiamine plus gemcitabine 
triggers pancreatic tumor cell apoptosis in vivo  
As shown by TUNEL assays (Fig. 7A and B), few 
cells underwent apoptosis in the control group, while 
significantly  more  apoptotic  cells  were  observed  in 
the  tumors  from  the  combination  treatment  group 
(P0.05  vs.  mice  treated  with  gemcitabine  alone  or 
controls). 
Evodiamine modulates the activation of 
phospho-mTOR(Ser2448) and phos-
pho-PTEN(Ser380) in tumor cells  
Consistent with the in vitro results, evodiamine 
alone  or  evodiamine  plus  gemcitabine  significantly 
reduced the expression of phospho-PTEN(Ser380) and 
phospho-mTOR(Ser2448)  in  transplanted  pancreatic 
cancer (Fig. 8A and B). 
 
 
 
 
Figure  7. Treatment with evodiamine enhances the gemcitabine-induced pancreatic cancer cell apoptosis in vivo. (A) 
TUNEL analysis of apoptotic cells (400x). (B) Quantitative analysis of apoptotic cells. Evo: Evodiamine; Gem: Gemcitabine. 
*P<0.05 vs. control; **P<0.05 vs. control or mice treated with single agent. Int. J. Biol. Sci. 2012, 8 
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Figure 8. Immunohistochemistry detection of phospho-mTOR(Ser2448) and phospho-PTEN(Ser380). (A) Evodiamine or 
evodiamine plus gemcitabine inhibit the activation of phospho-PTEN(Ser380) and phospho-mTOR(Ser2448). (B) Quantified 
data are presented. Evo: Evodiamine; Gem: Gemcitabine. 
#P>0.05 vs. control; *P<0.05 vs. control; **P<0.05 vs. control or 
mice treated with gemcitabine. 
 
Discussion 
Gemcitabine may activate NF-κB, and activation 
of NF-κB is believed to be one of the reasons for the 
development of chemoresistance during cancer ther-
apy. In fact, spontaneous activation of NF-κB has been 
detected in human pancreatic cancer tissues, and ac-
tivation of NF-κB is believed to result in the chemo-
resistant phenotype in pancreatic cancer cells (31-33). 
On the other hand, inactivation of NF-κB sensitizes 
cancer  cells  to  conventional  chemotherapies  (34-36). 
Evodiamine is widely believed to inhibit constitutive 
and inducible NF-κB activation (8) in several kinds of 
tumors,  such  as  lung  adenocarcinoma,  T-cell  lym-
phoma,  and  multiple  myeloma.  In  this  study,  we 
found that evodiamine potentiated anti-tumor effects 
of  gemcitabine  by  inhibiting  pancreatic  cancer  cell 
proliferation and inducing SW1990 cell apoptosis  in 
vitro  and  in vivo.  In  addition,  evodiamine  was  also 
found  to  inhibit  spontaneous  and  gemcita-
bine-induced  NF-κB  expression  and  activation  in 
SW1990 cells. Taken together, these findings suggest 
that evodiamine potentiates the cytotoxicity of gem-
citabine against pancreatic cancer cells by inhibiting 
the expression and activation of NF-κB. 
Previous studies have demonstrated that inhibi-
tion of NF-κB can potentiate the anti-cancer effect of 
multiple chemotherapeutic agents (36, 37). Similarly, 
siRNA-mediated  knockdown  of  survivin  expression 
was  reported  to  enhance  the  chemosensitivity  of 
pancreatic  cancer  cells  to  gemcitabine  (41).  In  this 
study, we found that gemcitabine-induced activation 
of  NF-κB  and  up-regulation  of  Bcl-2  and  survivin 
practically  undermined  its  proapoptotic  effect  on 
pancreatic  cancer  cells.  However,  evodiamine 
signiﬁcantly  down-regulated  the  gemcita-
bine-induced NF-κB activation and altered expression 
of  Bcl-2  and  survivin.  Moreover,  the  combination Int. J. Biol. Sci. 2012, 8 
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therapy  with  gemcitabine  and  evodiamine  also 
signiﬁcantly  up-regulated  Bax,  as  compared  to  sin-
gle-agent treatment, resulting in down-regulation of 
the Bcl-2/Bax ratio, and then increased the activation 
of caspase-3, which induced apoptosis. 
Earlier  reports  have  shown  that  treatment  of 
human  melanoma  A375-S2  cells  with  evodiamine 
negatively  affects  the  PI3K/Akt  signaling  pathway 
(25, 38). PI3K and Akt are both considered as viable 
and effective targets for pancreatic cancer therapy (38, 
39). Previous studies have also indicated that inhibi-
tion of Akt can enhance the activity of gemcitabine 
chemotherapy in pancreatic cancer (40-42). Here, we 
found that evodiamine alone or combined with gem-
citabine decreased the phospho-Akt(Ser473) levels in 
SW1990  cells,  implying  that  evodiamine  may  also 
potentiate  the  anti-tumor  activity  of  gemcitabine 
through  inhibiting  Akt  activation.  Fahy  et  al.  (43) 
showed  that  Akt  inhibition  sensitized  pancreatic 
cancer cells to the apoptotic effect of gemcitabine by 
suppressing the activity of NF-κB and reducing the 
Bcl-2/Bax  ratio  in  the  pancreatic  cancer  cell  line 
MIA-PaCa-2. Madrid et al. (44) demonstrated that the 
PI3K/Akt  pathway  is  involved  in  development  of 
chemoresistance, at least in part, by the activation of 
NF-κB.  In  our  study,  a  remarkable  deactivation  of 
NF-κB and decrease in the Bcl-2/Bax ratio in SW1990 
cells was detected in the evodiamine therapy group 
and in the evodiamine plus gemcitabine combination 
group. The PI3K signaling pathway has been shown 
to be activated in clinical samples of pancreatic cancer 
(17),  and  activation  of  PI3K  is  known  to  ultimately 
lead  to  Akt  phosphorylation  at  Thr308  and  Ser473 
(45). In the present study, we found that PI3K(Tyr458) 
in SW1990 cells was down-regulated in response to 
evodiamine  or  evodiamine  plus  gemcitabine  treat-
ments. PKA is the primary mediator of cAMP action 
and a key regulatory enzyme responsible for  many 
normal  cellular  processes,  such  as  cell  growth  and 
metabolism. Activation of PI3K/Akt can be achieved 
by cAMP-dependent PKA (46). Akt activation in hu-
man coronary artery endothelial cells was found to be 
inhibited by application of PI3K, Akt, or PKA inhibi-
tors  (46).  Here,  for  the  first  time,  we  demonstrated 
that  evodiamine  or  evodiamine  plus  gemcitabine 
down-regulated the activity of PKA in SW1990 cells, 
suggesting that inhibition of PI3K/Akt by evodiamine 
is partly due to suppressing PKA activity. It has been 
reported that cAMP formation up-regulates PI3K/Akt 
and PKA activities, leading to NF-κB activation (47). 
Here, we also found that evodiamine or evodiamine 
plus gemcitabine down-regulated the cAMP concen-
tration in SW1990 cells, suggesting that inhibition of 
PI3K/Akt by evodiamine is partly due to inhibition of 
cAMP/PKA. PI3K/Akt kinases phosphorylate multi-
ple  downstream  substrates,  including  the  ser-
ine/threonine protein kinase mTOR (48). A study by 
Sarbassov  et  al.  (49)  demonstrated  that  mTOR  in 
complex with Rictor:G_L targets AKT for phosphor-
ylation at Ser473. Therefore, interplay between mTOR 
and PI3K/Akt may exist. Since PTEN is known to be 
able to negatively affect the PI3K pathway in vivo (45), 
it  is  possible  that  dephosphorylation  of 
Ser380/Thr382/383 might indicate the up-regulation 
of  PTEN  phosphatase  activity,  a  critical  event  that 
leads  to  destabilization  and  down-regulation  of  the 
PI3K pathway (45). Our results showed that treatment 
with evodiamine alone or combined with gemcitabine 
decreased  the  expression  of  phos-
pho-PTEN(Ser380/Thr382/383),  phospho-mTOR 
(Ser2448)  and  Rictor-mTOR.  In  general,  our  study 
suggested  that  evodiamine  might  directly  or  indi-
rectly inhibit the PI3K/Akt pathway targeting NF-κB 
and inhibit the phosphorylation of PTEN and mTOR, 
thereby sensitizing pancreatic cancer cells to gemcita-
bine-induced apoptosis. 
We  found  that  evodiamine  significantly  aug-
mented the antitumor efficacy of gemcitabine in sub-
cutaneously implanted tumors. Experiments based on 
the luciferase-transfected SW1990 cells xenograft tu-
mor model also showed that evodiamine plus gem-
citabine were more efficacious for treating pancreatic 
cancer. Furthermore, the study also showed that evo-
diamine  and  evodiamine  plus  gemcitabine 
down-regulated  the  expression  of  phos-
pho-PTEN(Ser380) and phospho-mTOR(Ser2448), but 
gemcitabine had no remarked effect on their expres-
sion in tumor tissue, consistent with the in vitro results 
of Western blot analysis. 
Chemotherapeutic  agents  often  cause  various 
adverse  effects  in  patients.  Gastrointestinal  adverse 
effects,  such  as  anorexia,  constipation,  or  diarrhea 
often result in under nourishment and loss of body 
weight.  We  found  that  the  body  weight  of  mice 
treated with gemcitabine alone was significantly less 
than that of other groups. However, the body weight 
of the mice treated with both evodiamine and gem-
citabine  was  similar  to  that  of  controls.  These  data 
suggest that treatment with a reduced dose of gem-
citabine,  combined  with  evodiamine,  not  only  en-
hanced  the  antitumor  effect,  but  also  reduced  the 
gemcitabine-induced  body  weight  loss  in  mice.  A 
similar approach may also prevent and mitigate the 
side effect of gemcitabine treatment in patients with 
pancreatic  cancer  to  improve  the  life  quality  of  pa-
tients.  
In  conclusion,  our  data  indicated  that  evodia-
mine may augment the therapeutic effect of gemcita-Int. J. Biol. Sci. 2012, 8 
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bine in pancreatic cancer by direct or indirect inhibi-
tion of the PI3K/Akt pathway that was not influenced 
by gemcitabine and targeted NF-κB, thereby leading 
to sensitization of pancreatic cancer cells to gemcita-
bine. 
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